Bhatt, A. S. et al. (2023) Effect of dapagliflozin on health status and quality-of-life across the spectrum of ejection fraction: participant-level pooled analysis from the DAPA-HF & DELIVER trials. European Journal of Heart Failure, 25(7), pp. 981-988. (doi: 10.1002/ejhf.2909) (PMID:37211977)
Text
298809.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. 1MB |
Abstract
Background and aims: Coronary artery disease (CAD) is a common cause of heart failure (HF). Whether coronary revascularisation improves outcomes in patients with HF receiving guideline-recommended pharmacological therapy (GRPT) remains uncertain; therefore, we conducted a systematic review and meta-analysis of relevant randomized controlled trials (RCTs). Methods: We searched in public databases for RCTs published between 1st January 2001 and 22nd November 2022, investigating the effects of coronary revascularisation on morbidity and mortality in patients with chronic HF due to CAD. All-cause mortality was the primary outcome. Results: We included five RCTs that enrolled, altogether, 2,842 patients (most aged <65 years; 85% men; 67% with left ventricular ejection fraction ≤35%). Overall, compared to medical therapy alone, coronary revascularisation was associated with a lower risk of all-cause mortality (HR 0.88 [95% CI, 0.79-0.99]; p=0.0278) and cardiovascular mortality (HR 0.80 [95% CI, 0.70-0.93]; p=0.0024) but not the composite of hospitalisation for HF or all-cause mortality (HR 0.87 [95% CI, 0.74-1.01]; p=0.0728). There were insufficient data to show whether the effect of CABG or PCI were similar or differed. Conclusions: For patients with chronic HF and CAD enrolled in RCTs, the effect of coronary revascularization on all-cause mortality was statistically significant but neither substantial (HR 0.88) nor robust (upper 95% CI close to 1.0). RCTs were not blinded, which may bias reporting of the cause-specific reasons for hospitalization and mortality. Further trials are required to determine which patients with HF and CAD obtain a substantial benefit from coronary revascularization by either CABG or PCI.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Jhund, Professor Pardeep and McMurray, Professor John |
Authors: | Bhatt, A. S., Kosiborod, M. N., Vaduganathan, M., Claggett, B. L., Miao, Z. M., Kulac, I. J., Lam, C. S.P., Hernandez, A. F., Martinez, F., Inzucchi, S. E., Shah, S. J., de Boer, R. A., Jhund, P. S., Desai, A. S., Petersson, M., Langkilde, A. M., McMurray, J. J.V., and Solomon, S. D. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
Journal Name: | European Journal of Heart Failure |
Publisher: | Wiley |
ISSN: | 1388-9842 |
ISSN (Online): | 1879-0844 |
Published Online: | 21 May 2023 |
Copyright Holders: | Copyright © 2023 The Authors |
First Published: | First published in European Journal of Heart Failure 25(7):981-988 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record